-
Nanobiotix S.A (NBTX) PT Raised to $37 at Leerink Partners
-
NANOBIOTIX denies takeover speculation, cites media inaccuracies
-
Nanobiotix stock jumps on takeover report involving J&J
-
TD Cowen Highlights Nanobiotix S.A (NBTX) as 'Europe Best Ideas'
-
TD Cowen Starts Nanobiotix S.A (NBTX) at Buy
-
Nanobiotix S.A (NBTX) PT Raised to $26 at Leerink Partners
-
Nanobiotix S.A (NBTX) PT Raised to $24 at Leerink Partners
-
Nanobiotix S.A (NBTX) PT Lowered to $8 at Guggenheim
-
Nanometrics (NANO) Announces First Data From Completed Dose Escalation Part of Phase 1 Study Evaluating NBTXR3 as a 2L+ Therapy for Patients With Locally Advanced NSCLC
-
Guggenheim Starts Nanobiotix S.A (NBTX) at Buy

